A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors

被引：1
|
作者：
Banerji, Udai
Cook, Natalie
Anthoney, Alan
Plummer, Ruth
Tap, William D.
Evans, Jeffry T.
Cranmer, Lee D.
Plummer, Christopher
Loadman, Paul
Lahu, Gezim
Jones, Huw S.
Kinnersley, Nelson
McLaughlin, Fiona
Twelves, Chris
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT188
引用
收藏
页数：2
相关论文
共 2 条
  • [1] A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    Twelves, C. J.
    Banerji, U.
    Tap, W. D.
    Cook, N.
    Evans, T. R. J.
    Plummer, R.
    Anthoney, A.
    Plummer, C.
    Dawson, R.
    Loadman, P.
    Lahu, G.
    Jones, H.
    Kinnersley, N.
    Edwards, R.
    Gordon, G.
    Cranmer, L. D.
    ANNALS OF ONCOLOGY, 2024, 35 : S511 - S511
  • [2] AVA6000, a novel Precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage
    McLaughlin, Fiona
    Poplawski, Sarah E.
    Sanford, David G.
    Saunders, Andrew
    Lai, Jack H.
    Vincent, Matthew
    Bachovchin, William W.
    Bell, Neil
    CANCER RESEARCH, 2022, 82 (12)
1